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Abstract
Background: Numerous hypermethylated genes have been reported in breast cancer, and the silencing of these 
genes plays an important role in carcinogenesis, tumor progression and diagnosis. These hypermethylated promoters 
are very rarely found in normal breast. It has been suggested that aberrant hypermethylation may be useful as a 
biomarker, with implications for breast cancer etiology, diagnosis, and management. The relationship between primary 
neoplasm and metastasis remains largely unknown. There has been no comprehensive comparative study on the 
clinical usefulness of tumor-associated methylated DNA biomarkers in primary breast carcinoma and metastatic breast 
carcinoma. The objective of the present study was to investigate the association between clinical extension of breast 
cancer and methylation status of Estrogen Receptor1 (ESR1) and Stratifin (14-3-3-σ) gene promoters in disease-free and 
metastatic breast cancer patients.
Methods: We studied two cohorts of patients: 77 patients treated for breast cancer with no signs of disease, and 34 
patients with metastatic breast cancer. DNA was obtained from serum samples, and promoter methylation status was 
determined by using DNA bisulfite modification and quantitative methylation-specific PCR.
Results: Serum levels of methylated gene promoter 14-3-3-σ significantly differed between Control and Metastatic 
Breast Cancer groups (P < 0.001), and between Disease-Free and Metastatic Breast Cancer groups (P < 0.001). The ratio 
of the 14-3-3-σ level before the first chemotherapy cycle to the level just before administration of the second 
chemotherapy cycle was defined as the Biomarker Response Ratio [BRR]. We calculated BRR values for the "continuous 
decline" and "rise-and-fall" groups. Subsequent ROC analysis showed a sensitivity of 75% (95% CI: 47.6 - 86.7) and a 
specificity of 66.7% (95% CI: 41.0 - 86.7) to discriminate between the groups for a cut-off level of BRR = 2.39. The area 
under the ROC curve (Z = 0.804 ± 0.074) indicates that this test is a good approach to post-treatment prognosis.
Conclusions: The relationship of 14-3-3-σ with breast cancer metastasis and progression found in this study suggests a 
possible application of 14-3-3-σ as a biomarker to screen for metastasis and to follow up patients treated for metastatic 
breast cancer, monitoring their disease status and treatment response.
Background
B r eas t  ca n c e r  is  a  m a j o r  h ea l t h  p r o b l e m ,  wi t h  m o r e
than 1,000,000 new cases and 370,000 deaths annually
worldwide. Over the past decade, breast cancer mor-
tality has been declining in the majority of developed
countries, despite an increasing incidence. This is the
combined result of better education, widespread
screening programs, and more efficacious adjuvant
treatments. Furthermore, improved knowledge of
breast cancer biology now allows the majority of breast
cancer patients to be spared the cosmetic, physical,
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and psychological consequences of radical treatment,
including radiotherapy [1-3].
However, clinicians have limited instruments available
for the early detection of breast cancer recurrence that
results from metastases undetected at the time of the pri-
mary treatment. Molecular studies have yielded impor-
tant data on breast cancer development and progression.
However, no biomarkers, used alone or together, have yet
proved able to definitively predict the outcome of cancer
treatment, and new molecules are required that can serve
a s  r e l i a b l e  i n d i c a t o r s  o f  t h e  r i s k  o f  c a n c e r  r e c u r r e n c e .
Serum biomarkers are produced by body organs or
tumors, and large amounts in the blood can be suggestive
of tumor activity [4]. The only breast cancer tumor mark-
ers with demonstrated clinical utility are tumor-associ-
ated antigens, but their usefulness to follow up patients
with metastatic disease can be limited [5].
A key challenge in breast cancer therapy is to elucidate
the mechanisms involved in inducing or repressing the
multiple genes required for cancer cell growth, invasion,
and metastasis. Methylation-associated changes affect
numerous genes in all cellular pathways [6], and it is
widely accepted that a succession of accumulative hits in
oncogenes lead to genetic lesions. The pathological fea-
tures of breast cancer follow a sequential progression
from the transition of a normal cell to benign proliferative
hyperplasia, hyperplasia with atypia, carcinoma in situ,
and, eventually, invasive and metastatic disease [7]. How-
ever, the timetable of epigenetic alterations during this
progression is little understood [8]. Some studies have
evaluated the association between gene hypermethyla-
tion and biological or clinical properties of breast tumors
[9-12].
In breast cancer, tumor-related genes may be silenced
by hypermethylation. DNA methylation, unlike other epi-
genetic changes, does not alter the nucleotide sequence.
Hypermethylation is an epigenetic change that blocks the
promoter region of a gene and results in gene silencing.
When CpG islands are hypermethylated, the activity of
the regulatory proteins that promote transcription is
restricted due to the tightly packed nucleosomes[13].
Many hypermethylated genes have been reported, and
silencing of these genes plays an important role in car-
cinogenesis, tumor progression [9,14], and diagnosis
[11,15-17]. These hypermethylated promoters are very
rarely found in normal breast. It has been suggested that
aberrant hypermethylation may be useful as a biomarker,
with implications for breast cancer etiology, diagnosis,
and management.
The epigenetic alterations that initiate and drive tum-
origenesis are promising targets for the early detection of
tumor and perhaps metastasis, because they may precede
clinical signs of cancer or recurrence and can be detected
at very low levels [11]. The relationship between primary
neoplasm and metastasis remains largely unknown [18].
There has been no comprehensive comparative study on
the clinical usefulness of tumor-associated methylated
DNA biomarkers in primary breast carcinoma and meta-
static breast carcinoma.
Although numerous issues remain to be resolved, the
quantitative measurement of circulating methylated
DNA remains a promising approach to cancer risk assess-
ment. The objective of the present study was to assess the
usefulness of serum concentrations of methylated Estro-
gen Receptor1 (ESR1) and Stratifin (14-3-3-σ) gene pro-
moters in breast cancer patients in two very different
clinical situations: i) treated and with no evidence of
residual or recurrent disease, and ii) treated and with
detected metastatic breast cancer. We also examined
whether these biomarkers add information of clinical
utility during the post-treatment follow-up of breast can-
cer patients with metastases.
Methods
Samples
Blood samples (7 ml) were obtained from all study partic-
ipants by venipuncture. All samples were randomly coded
before processing to ensure that analysts were blinded to
their origin. Samples were centrifuged at 2000 g for 10
m in a t  r oo m t e m pe r a t ur e ,  a nd 1-m l  a l iquo ts  of  serum
samples were carefully transferred into new tubes. Sera
were stored at -80°C until their analysis (between June
2008 and March 2009). Full clinical and pathological data
were collected and known for all participants. Patient
characteristics are summarized in Table 1. This research
was approved by the Institutional Ethics Committees of
the Negrín Hospital, Gran Canaria and the Virgen de las
Nieves Hospital, and the University of Granada, Spain,
and written informed consent was obtained from all
study participants.
Patient groups were formed as follows:
a) Disease-Free Breast Cancer group [DFBC]. A
group of 77 consecutive women surgically treated at
Hospital Negrín, Gran Canaria, Spain for localized
operable breast cancer without clinical or radiological
evidence of distant metastases were enrolled in this
study between May 2007 and December 2008.
b) Metastatic Breast Cancer Group [MBC]. Samples
were obtained from 34 consecutive patients with met-
astatic breast cancer disease treated in the Virgen de
las Nieves Hospital, Granada, Spain. Samples were
taken on the day that each chemotherapy cycle
started, gathering a series of sequential samples for
each patient from the first to the last CT cycle.
c) Healthy Control Group, [HC]. An age-matched
s a m p l i n g  a p p r o a c h  ( w i t h  F D B C  g r o u p )  w a s  u s e d ,
obtaining blood samples from 34 women randomly
selected from among healthcare professionals of ourZurita et al. BMC Cancer 2010, 10:217
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Table 1: Clinical and pathological characteristic of the breast cancer patients
Characteristics Disease-Free Breast Cancer Group Metastatic Breast Cancer Group
Histological type
Invasive ductal carcinoma 63 (81.8%) 22 (64.7%)
Invasive lobular carcinoma 8 (10.4%) 6 (17.6%)
Other invasive carcinoma 6 (7.8%) 4 (11.4%)
Unknown 0 2 (5.8%)
Histological grade
Grade I 17 (22.1%) 1 (2.9%)
Grade II 25 (32.5%) 8 (23.5%)
Grade III 26 (33.8%) 20 (58.8%)
Unknown 9 (11.7%) 5 (14.7%)
Tumor size
Tis 2 (2.6%) 1 (2.9%)
T1 40 (52.0%) 10 (29.4%)
T2 24 (31.2%) 13 (38.2%)
T3 7 (9.1%) 5 (14.7%)
T4 4 (5.2%) 2 (5.8%)
Tx 0 1 (2.9%)
Unknown 2 (5.8%)
Node involvement
N0 41 (53.3%) 13 (38.2%)
N1 26 (33.8%) 8 (23.5%)
N2 6 (7.8%) 9 (26.4%)
N3 3 (3.9%) 2 (5.8%)
Nx 1 (1.3%) 2 (5.8%)
Estrogen receptor status
Negative 20 (25.1%) 10 (27.7%)
Positive 53 (68.8%) 21 (61.7%)
Unknown 4 (5.2%) 3 (8.8%)
Progesterone receptor status
Negative 23 (30.0%) 10 (29.4%)
Positive 50 (64.9%) 22 (64.7%)
Unknown 4 (5.1%) 2 (5.8%)
Menopause
Yes 46 (62.3%) 31 (91.1%)
No 26 (33.8%)
Unknown 3 (3.9%) 3 (8.8%)Zurita et al. BMC Cancer 2010, 10:217
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hospital undergoing regular health examinations at
the Department of Preventive Medicine.
DNA isolation
DNA from serum samples (2 ml per column) was
obtained by using QIAmp DNA Blood Kit (QIAGEN Inc.,
CA) according to manufacturer's recommendations. A
final elution volume of 200 μl was established. Extracted
DNA was quantified spectrophotometrically. The
amount of DNA recovered was measured as μg/sample.
DNA samples were stored at -80°C until use.
DNA bisulfite modification and real-time QMS-PCR using 
SYBR green
Identical DNA sequences that differ only in methylation
status [19] can be amplified by means of Quantitative
Methylation Specific PCR (QMS-PCR). Reagents
required for the bisulfite modification of DNA were sup-
plied in the CpGenomeTM DNA Modification Kit (Inter-
gen, MA). The process was performed according to
manufacturer's recommendations. Sufficient DNA can be
recovered to perform MSP from an amount of starting
material as small as 0.001 μg. In brief, 100 μl of extracted
DNA was treated with sodium bisulfite for 16 h, thereby
converting all unmethylated cytosines to uracils but leav-
ing methylcytosines unaltered. Efficiency of DNA recov-
ery after bisulfite modification was around 55% (data not
shown). One microliter of the recovered bisulfite-treated
DNA was used in each well for SYBR green reaction.
Modified DNA of standards and samples are stable for at
least 2 months at -80°C. A sample of bisulfite-modified
universally methylated DNA genome (CpGenomeTM
Universal Methylated DNA, Intergen, New York, USA),
treated in the same way as patient samples and adjusted
after modification to 2 μg/ml (quantified spectrophoto-
metrically), served as internal standard to prepare serial
dilutions (from 1 to 1/128) with MiliQ water to construct
a Standard Curve for Real-Time QMS-PCR. Each plate
contained patient samples, serial dilutions of completely
methylated DNA for constructing calibration curves,
positive controls, and two wells with water blanks used as
negative controls. In all cases, correlation coefficients for
the calibration curves were higher than 0.98, slopes
ranged from 3.2 to 3.4, and PCR efficiencies were around
100%.
The reaction mixture contained 1 μl of modified serum
DNA of each standard or unknown sample as template
for real-time QMS-PCR, 0.5 μM of each oligonucleotide
primer, 12.5 μl of 2× SYBR Green Supermix (Bio-rad),
and sterile water. All PCR experiments were performed in
a volume of 25 μl with 96-well plates. Primer sequences
were obtained from previously published data for strati-
fin (14-3-3-σ) [20] and estrogen receptor-α (ESR1) [21].
The fluorescence signal of the quantitative methylation-
specific PCR was generated by SYBR Green Super Mix
(BioRad, Hercules, CA). PCR amplification was done by
using a previously reported procedure [11]. The fluores-
cence value after QMS-PCR in each sample was con-
verted into units of universally methylated DNA (μg/ml),
which we designated "relative units", using the corre-
sponding PCR Standard Curve obtained from the iCycler
iQ software. Results obtained in a previous study [11]
indicated that the method was valid for this investigation.
Statistical analysis
The associations of the two biomarkers with breast can-
cer presence, their capacity to discriminate between
women with and without clinical and radiological evi-
dence of breast cancer metastasis, and their post-chemo-
therapy behavior were analyzed in the following phases:
(1) Descriptive analysis of the three groups (DFBC,
MBC, and HC) was performed for each biomarker,
expressing results as means and standard error of the
means (SEM).
(2) The Kruskal-Wallis test was used to study differ-
ences among groups (DFBC, MBC, and HC), and the
Dunn's multiple comparison test was used for paired
comparisons when results were significant.
(3) Effects of the chemotherapy on serum ESR1 and 14-
3-3-σ levels were studied using Wilcoxon signed rank test
and paired test.
(4) Effects of the chemotherapy on treated patients with
detected metastatic breast cancer were measured accord-
ing to the following scoring system: Measurable
Response. (MR): disappearance or decrease of all signs
and symptoms of the lesions, no growth of any lesion, and
no appearance of a new lesion. Stable Disease (SD): no
significant changes in lesion size or in any tumor-related
signs or symptoms. Progression (P): measurable increase
in lesion size or appearance of new lesions. Mortality dur-
ing treatment (MDT): patients dying during the chemo-
therapy period.
(5) Biomarker Response Ratio (BRR). The ratio of the
14-3-3-σ level before the first chemotherapy cycle to the
level just before administration of the second chemother-
apy cycle was defined as the BBR.
(6) ROC curves: The distributions of the 14-3-3σ ratio
values corresponding to different patient populations are,
at least in part, overlapped. As a consequence, the num-
ber of correct predictions of the measurable response
(true positive (TP) cases identified by means of the test
depends on the threshold level selected. Using different
thresholds, it is possible to obtain successive pairs of false
positive (FP) and TP values that can be plotted as a curve.
A useful numerical parameter arising from this graph is
the proportion of ROC space that lies below the ROC
curve (Z).Zurita et al. BMC Cancer 2010, 10:217
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Results
Table 1 shows the general characteristics of the two
patient groups studied. The groups did not differ in histo-
logical type (P > 0.05), estrogen receptor status (P > 0.05)
or iii) progesterone receptor status (P > 0.05). As
expected, they significantly differed in tumor size (P <
0.05), nodal involvement (P < 0.05), and histological
grade (P < 0.05).
Median serum levels of methylated gene promoter
ESR1 did not differ among HC, DFBC, and MBC groups
(P > 0.05). Median serum 14-3-3-σ values did not differ
between HC and DFBC groups (P > 0.05), but differed
between HC and MBC groups (P < 0.001) and between
DFBC and MBC groups (P < 0.001). Figure 1 depicts the
results obtained.
Calculation of the area under the ROC curve (Z) for the
capacity of 14-3-3-σ  to discriminate between healthy
individuals and patients with breast cancer metastatic
disease gave a value of Z = 0.925 (95% confidence inter-
val: 0.886 to 0.964), an excellent level of accuracy.
Figure 2 depicts 14-3-3-σ gene values before and after
the first chemotherapy cycle, showing that the chemo-
therapy produced a major reduction in the serum levels
of 14-3-3-σ in the MBC group. These differences have
been studied using Wilcoxon signed rank test and show
that the median difference in methylation after treatment
is greater than zero (P = 0.0045); being the paired test also
significant (P = 0.012).
However, although initial levels appear to fall in
most of the MBC patients, other patients show no
change or an increase in levels. Figure 3 shows those
MBC patients with a continuous decline in serum 14-
3-3-σ, and Figure 4 those patients with both rises and
falls. This biomarker-based categorization has been
empirically defined. Table 2 shows the contingency
table that was constructed by combining this bio-
marker's response-pattern with the chemotherapy
response scores. Analysis with the Pearson chi-square
test gave a value of 10.23 (P = 0.017), indicating that
the time course of the biomarker was determined by
the clinical response to the treatment. In summary,
the continuous-decline pattern of serum 14-3-3-σ lev-
els was associated with a positive predictive value of
65% (95% CI 38-86%), implying a favorable prognosis
in two out of three patients, whereas the rise-and-fall
pattern was associated with a negative predictive
value of 88%, implying a poor prognosis for most of
the patients with this pattern.
Finally, we calculated the ratio of the 14-3-3-σ level
before the first chemotherapy cycle to the level just
before administration of the second chemotherapy cycle
for the "continuous decline" and "rise-and-fall" groups
(figure 5). The median values are: 5.606 and 1.694,
respectively and the medians, Mann Whitney test, are
significantly different (P = 0.0034).
Figure 1 The box and whisker plot shows the median value and 10-90 percentiles of biomarkers, ESR1 and 14-3-3-σ, measured in the serum 
of the individuals in each of the three study groups: Healthy Controls (HC); Disease-Free Breast Cancer (DFBC); and Metastatic Breast Can-
cer (MBC). 14-3-3-σ values significantly differed between the DFBC and MBC groups (Dunn test, P > 0.0001) and between each of these and the HC 
group (P < 0.001).
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Figure 2 14-3-3-σ values measured in serum of patients with met-
astatic breast cancer disease before and after the first chemo-
therapy cycle. Wilcoxon signed rank test, P = 0.0045.Zurita et al. BMC Cancer 2010, 10:217
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Discussion
Accurate prognosis and predictive factors are necessary
for the optimum management of patients with cancer and
are especially important in breast cancer, because of its
widely varying outcomes and the availability of poten-
tially beneficial systemic adjuvant therapies. The defini-
tive assessment of the clinical value of a predictive factor
is a long process [4], but the use of an unbiased genome-
wide approach has permitted the rapid identification of a
number of genes that strongly predict a poor clinical out-
come [22]. The identification of mutations and/or epige-
netic alterations in cancer may be useful to develop novel,
more effective biomarkers and therapies in breast and
colon cancer [22]. In breast cancer, promoter hypermeth-
ylation has been reported for various genes that cover
most cell functions [11,15,17,23,24].
Estrogen receptor status is an important factor in the
diagnosis and prognosis of breast cancer. A previous
study by our group found a significant difference in
serum values of ESR1  and  14-3-3-σ  gene promoters
between breast cancer patients and healthy controls [11].
The present study also found a significant difference in
serum methylated 14-3-3-σ gene promoter between met-
astatic breast cancer patients and healthy controls. In
contrast, however, ESR1 appeared to be unmethylated in
the present patients with metastatic breast cancer. Theo-
retically, ESR1 is considered to be preferentially methy-
lated in tumors because its inactivation confers a selective
clonal advantage[25]. It is possible that the specific envi-
ronmental and nutritional setting of breast cancer metas-
tases produces changes in this epigenetic alteration.
However, further in-depth study is required to explain
this intriguing finding. Reports of differences in methyla-
tion pattern between primary and metastatic breast can-
cer [18] may indicate that therapeutic targets in primary
breast cancer are not be the same as targets in metastatic
sites.
14-3-3 proteins are crucial in a wide variety of cell
responses, including DNA damage checkpoints and
apoptosis [26]. Disruption of the G2-M checkpoint also
appears to contribute to the change in the sensitivity of
cells to chemo- and radiotherapy [27,28]. 14-3-3 sigma
sequesters the cdc2-cyclin B1 complex in the cytoplasm,
resulting in G2 arrest. Among the genes involved in the
G2-M checkpoint, 14-3-3σ, a transcriptional target of
p53, is frequently silenced by DNA methylation of the 14-
3-3σ gene promoter or by induction of estrogen-respon-
sive ubiquitin ligase that specifically targets 14-3-3σ for
proteosomal degradation [23,29]. The inactivation and
reduced expression of 14-3-3σ have been reported in var-
Table 2: Patients' summary score distribution (treatment response distribution) according to the biomarker pattern 
observed during the treatment time-course.
Pattern MR SD P MDT
Continuously decline 11 2 3 1
R i s e  a n d  f a l l 2663
MR: Measurable Response; SD: Stable Disease; P: Progression; MDT: Mortality during treatment
Figure 3 14-3-3-σ values measured in serum of patients with 
breast cancer metastatic disease before the first C(0) and succes-
sive C(1...5) chemotherapy cycles, in patients with "continuous 
decline" biomarker pattern.
Figure 4 14-3-3-σ values measured in serum of patients with 
breast cancer metastatic disease before the first C(0) and succes-
sive C(1...5) chemotherapy cycles, in patients with "rise-and-fall" 
biomarker pattern.Zurita et al. BMC Cancer 2010, 10:217
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ious cancers, including breast cancer [16,26,30]. To date,
the sigma isoform of 14-3-3 proteins has been the iso-
form most directly implicated in carcinogenesis and is
recognized as a tumor-suppressor gene [31]. Although
the molecular basis for the tumor-suppressor function of
14-3-3σ is unknown [26], it has been suggested that 14-3-
3σ is a critical regulator of G2-M [32]. It has also been
demonstrated that endogenous 14-3-3σ preferentially
forms homodimers in cells [33]. Knocking out 14-3-3σ in
cancer cells leads to mitotic catastrophe and cell death
from DNA damage due to the absence of G2-M arrest
[34]. Moreover, the highly conserved human 14-3-3 gene
family encodes proteins with either tumor-promoting or
tumor-suppressing activities, suggesting that the cellular
balance among different 14-3-3 isoforms is crucial for the
proper functioning of cells [32]. 14-3-3 proteins have
been found in primary breast cancer, enhancing its bio-
logical activity [35]. The structure of the p53 C-terminus
bound to the adaptor protein 14-3-3 has been recently
described, providing a rationale for the observed stabiliz-
ing effect of 14-3-3 binding [36]. Consistent with these
data, the G2-M checkpoint is impaired in cancer cell lines
that show methylation of 14-3-3 σ, while restoration of
the expression of these genes using 5-aza-dC restores G2-
M arrest induced by DNA damage [37]. This molecule
also contributes to mitotic catastrophe in carcinoma cells
treated with chemotherapy agents [38].
Results of a recent study [39] showed that 14-3-3 and
HSP70 expression may be useful as biomarkers and tar-
gets for the diagnosis and treatment of human triple-neg-
ative breast cancer. Breast cancer metastasis is the main
cause of treatment failure, and the goal of adjuvant ther-
apy is to eliminate disseminated tumor cells after com-
plete removal of the tumor. However no tool is available
to monitor its efficacy [11]. Response to adjuvant treat-
ment is usually evaluated retrospectively based on recur-
rence and survival rates. Therefore, the identification of
metastasis biomarkers at an early stage may contribute to
the early diagnosis and treatment of breast cancer
patients. There is increasing recognition of the impor-
tance of epigenetic changes in the metastatic process.
Cells may acquire an epi-genotype that allows them to
disseminate from the primary tumor mass or survive and
proliferate at a secondary tissue site [40]. Overall, these
results offer evidence of a difference in protein profile
between metastatic and primary breast cancer.
The expression profile of the metastatic tumor is
known to differ between primary tumor and heteroge-
neous metastasis [39]. The present findings show that
breast cancer methylation profiling might yield biomark-
ers for the diagnosis and treatment efficacy of breast can-
cer metastasis. Thus, we found that ROC analysis of
serum levels of 14-3-3-σ methylated gene-promoter dis-
criminated between healthy individuals and metastatic
breast cancer patients with a sensitivity of 81% (95% CI:
74.0 - 86.8) and a specificity of 96.2% (95% CI: 80.45 -
99.9), making this biomarker a candidate for use in
metastasis screening in the follow-up of treated breast
cancer patients. It would be of special interest to investi-
gate whether the elevated post-surgical serum 14-3-3-σ
levels in some of the present patients (DFBC group) and
in our previous study [11] indicate a risk of metastatic
cancer or tumor recurrence. Although this type of inves-
tigation requires a prolonged follow-up [4], identification
Figure 5 Discriminatory power of the biomarker response ratio [14-3-3-σ BRR] to predict the outcome in patients with metastatic breast 
cancer treated with chemotherapy. A: Comparison between treatment outcomes; B: ROC curve.Zurita et al. BMC Cancer 2010, 10:217
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of this biomarker as a risk factor and its correlation with
other clinical factors may lead to improvements in breast
cancer treatment.
14-3-3-σ proteins are known to be crucial in a wide
variety of cell responses, including cell cycle progression,
DNA damage checkpoints, and apoptosis [26], and 14-3-
3-σ  hypermethylation is a significant event in primary
breast cancer [41]. However, its impact on tumor pro-
gression and its potential as a predictive factor remain
unknown. Because 14-3-3-σ proteins regulate normal cell
processes, the loss of their expression (mainly by hyperm-
ethylation of 14-3-3-σ gene promoter) may be implicated
in breast cancer progression [31,42]. This hypothesis is
supported by our data, since hypermethylation of 14-3-3-
σ was significantly associated with the response to meta-
static breast cancer treatment. We calculated BRR values
for the "continuous decline" and "rise-and-fall" groups
(values plotted in Figure 5A). Analysis by unpaired t-test
with Welch's correction showed a significant difference in
mean values between these groups (P = 0.021). Subse-
quent ROC analysis, considering the "continuous decline
group" as controls and the rise-and-fall group as cases
(Figure 5B), showed a sensitivity of 75% (95% CI: 47.6 -
86.7) and a specificity of 66.7% (95% CI: 41.0 - 86.7) to
discriminate between the groups for a cut-off level of
BRR = 2.39.
The area under the ROC curve (Z = 0.804 ± 0.074) indi-
cates that this test is a good approach to post-treatment
prognosis and supports the very recent idea that 14-3-3
proteins may be related to breast cancer metastasis and
evolution [43]. However, a small amount of 14-3-3-σ
methylated was detected in sera from healthy controls
[11], which may be explained by presence of occult
benign breast disease, although other possible sources of
this DNA include: normal tissues, which show higher
methylation values with increasing age[44]; leukocytes
[23], or breast benign disease [41]. The above findings
raise some questions about the utilization of 14-3-3-σ
gene promoter in DNA extracted from serum for metas-
tasis screening in the follow-up of treated breast cancer
patients. Further research is warranted to elucidate this
issue and to establish the impact of 14-3-3σ on tumor
progression and its potential to predict the response to
treatment of metastatic breast cancer.
Conclusions
There are numerous promising treatments for advanced
breast cancer now in phase III trial, and there is an urgent
need to establish sensitive end-points that can be
assessed earlier than overall survival [45]. Although fur-
ther research is required to establish the link between 14-
3-3-σ hypermethylated gene promoter measured in the
serum of breast cancer patients and the response to che-
motherapy, including control of symptoms, avoidance of
adverse effects, and improvement in quality of life,
important aspects in the approaching era of personalized
medicine, this biomarker may be potentially useful to
monitor disease status and treatment response.
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